Who makes SLITone ULTRA HDM immunotherapy?

SLITone ULTRA HDM immunotherapy is developed by ALK-Abelló A/S.

What development phase is SLITone ULTRA HDM immunotherapy in?

SLITone ULTRA HDM immunotherapy is in Phase 2.

Last reviewed 2026-05-13 · How we verify

SLITone ULTRA HDM immunotherapy

ALK-Abelló A/S · Phase 2 active Biologic

At a glance

Generic name	SLITone ULTRA HDM immunotherapy
Sponsor	ALK-Abelló A/S
Modality	Biologic
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Dose Response Evaluation of SLITone Ultra HDM Mix Immunotherapy (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

SLITone ULTRA HDM immunotherapy CI brief — competitive landscape report
SLITone ULTRA HDM immunotherapy updates RSS · CI watch RSS
ALK-Abelló A/S portfolio CI